{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:42:06Z","timestamp":1791996126076,"version":"4.4.0"},"reference-count":9,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2019]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Objectives:&lt;\/i&gt;&lt;\/b&gt; We aimed to identify an optimal regimen for low-risk gestational trophoblastic neoplasia (LR-GTN) providing reduction in dosage and toxicity\/side effects, enhancement of therapeutic efficacy, and a shorter treatment duration. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; A total of 149 LR-GTN patients were enrolled in the affiliated Beijing Maternity Hospital of Capital Medical University from January 2014 to January 2017 and randomly divided into 3 groups with 50 cases in the methotrexate (MTX) group, 49 in actinomycin D (ACT-D) group, and 50 in ACT-D+MTX group. Follow-up recorded symptoms, physical and bimanual gynecological examinations, routine blood test, serum \u03b2-HCG level, liver and renal functions, electrolytes, electrocardiogram before each treatment course, and pelvic and abdominal B-mode ultrasound or pelvic\/abdominal\/chest computed tomography. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; Serum complete remission (SCR) was 96.0, 87.8, and 83.7% for the ACT-D+MTX, ACT-D, and MTX groups, respectively, with SCR being highest in the ACT-D+MTX group, statistically higher than in the MTX group. Vomiting was the only side effect differing significantly by chemotherapy regimen, with a distinctly higher incidence in the ACT-D+MTX group compared with the MTX group (&lt;i&gt;p&lt;\/i&gt; = 0.028). The reduction rate of serum \u03b2-HCG in the ACT-D+MTX group was significantly greater than in the other 2 groups. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; Combined ACT-D+MTX chemotherapy achieved overall better efficacy and showed less toxicity than ACT-D or MTX alone, and thus can be prioritized for the treatment of LR-GTN.<\/jats:p>","DOI":"10.1159\/000500165","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T21:00:34Z","timestamp":1559682034000},"page":"42-47","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of Combination Therapy with Actinomycin D and Methotrexate in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia"],"prefix":"10.1159","volume":"64","author":[{"given":"Hai-Li","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2019,6,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.06.004"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1590\/SO100-720320140005198"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2015.1136778"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jog.12613"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007102.pub4"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.0151"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.10.2769"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.4386"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.10.007"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/500165","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/500165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:35:19Z","timestamp":1745426119000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000500165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":9,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,7,17]]}},"URL":"https:\/\/doi.org\/10.1159\/000500165","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"value":"0009-3157","type":"print"},{"value":"1421-9794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}